Biological
DTaP-IPV-HB-PRP-T vaccine clinical trials
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Meningococcal Vaccines (2) · Acetaminophen (1) · Vaxelis (1) · Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (1) · Rotavirus Vaccines (1) · 13-valent pneumococcal vaccine (1) · Measles Vaccine (1) · Pentavac (1)
Studies
Open first, then newest update. How each study uses DTaP-IPV-HB-PRP-T vaccine is read from its arms, and is right about nine times in ten.
Testing it · 6
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South AfricaCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT05794230Written as DTaP-IPV-Hib-HepB vaccine
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and InfantsActive, not recruitingPhase 1/2Sanofi Pasteur, a Sanofi CompanyNCT06647407Written as DTap-HepB-IPV-Hib vaccine
- Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and MexicoCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03630705Written as Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine
- Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After BirthCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT02428491Written as Hexaxim®
- DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected InfantsCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT02817451Written as Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine
- Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at BirthCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT01948193Written as Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine
Given in every arm · 2 — DTaP-IPV-HB-PRP-T vaccine is usual care beside what is tested
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3Sanofi Pasteur, a Sanofi CompanyNCT06736041Written as Hexaxim Vaccine
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06975878Written as Hexyon vaccine
Codes
What other systems call DTaP-IPV-HB-PRP-T vaccine · ClinicalTrials.gg INT000859
- MeSH (NLM) C000625558DTaP-IPV-HB-PRP-T vaccineOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000625558 | DTaP-IPV-HB-PRP-T vaccine | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.